Skip to content

Innoviva, Inc. INVA Equity Method Investments

Equity Method Investments at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$31.52M
Alkermes logo
AlkermesALKS
$26.36M-18.1%
Royalty Pharma logo
Royalty PharmaRPRX
$265.7M-21.0%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$29.6M+13.0%

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.41B+9.7%
P/E3.5×
P/S4.2×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermInvestments.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s equity method investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s equity method investments?
Innoviva, Inc. (INVA) reported equity method investments of $413.08M in Q1 2026.
How has Innoviva, Inc.'s equity method investments changed year-over-year?
Innoviva, Inc.'s equity method investments increased by 41.9% year-over-year, from $291.1M to $413.08M.
What is the long-term trend for Innoviva, Inc.'s equity method investments?
Over 5 years (2020 to 2025), Innoviva, Inc.'s equity method investments has grown at a -1.6% compound annual growth rate (CAGR), from $438.26M to $404.5M.
What does equity method investments mean?
Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.